Instrumento Inactivo

Otros idiomas Caladrius Biosciences Inc Nasdaq

Acciones

US1280581042

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

09/05	Transcript : Lisata Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Lisata Therapeutics, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	08/05
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	08/05
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	02/05
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	02/05
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	24/04
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	23/04
Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	23/04
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	17/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	03/04
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	21/03
Sector Update: Health Care Stocks Higher in Afternoon Trading	21/03
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	21/03
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	21/03
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	04/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Caladrius Biosciences Inc Nasdaq

Acciones

US1280581042

Otros idiomas

Filtros